Home › Trial NCT05433480
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
- Trial IDNCT05433480
- StatusUnknown
- PhasePhase 3
- Study typeInterventional
- SponsorBetta Pharmaceuticals Co., Ltd.
- Enrollment274
- Start date2022-05-25
- ConditionsBreast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.